Inhye Ahn, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Inhye Ahn, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:34 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07052695 · Mosunetuzumab for CLL MRD ClearanceInhye Ahn · recruiting · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- N/ANCT05521178 · Cardiotoxicities in Patients Receiving BTKiDana-Farber Cancer Institute · withdrawn · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT04685915 · Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLInhye Ahn · withdrawn · Chronic Lymphocytic Leukemia (CLL) · principal investigator
- Ph1NCT03219450 · A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.Dana-Farber Cancer Institute · recruiting · Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.